𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells

✍ Scribed by Kawashima, Hidenori ;Tanaka, Tomoaki ;Cheng, Jed-Sian ;Sugita, Syozo ;Ezaki, Kazuyoshi ;Kurisu, Takeshi ;Nakatani, Tatsuya


Publisher
Springer
Year
2004
Tongue
English
Weight
284 KB
Volume
32
Category
Article
ISSN
0300-5623

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Androgen receptors, androgen-dependent p
✍ M. Maasberg; M. Rotsch; G. Jaques; U. Enderle-Schmidt; R. Weehle; K. Havemann πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 French βš– 703 KB

We investigated the influence of testosterone on binding to established small-cell lung cancer (SCLC) cell lines and were able to show specific high-affinity and low-capacity binding sites in some cell lines with a typical receptor size, using sucrose density gradient centrifugation. In addition, we

Relation between Bcl-2, cell proliferati
✍ Bonkhoff, Helmut; Fixemer, Thomas; Remberger, Klaus πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 401 KB πŸ‘ 2 views

## Background: Several recent studies have suggested an important role of the apoptosis suppressing bcl-2 gene product in prostate cancer progression to an androgen-insensitive disease. ## Methods: Using double-labeling techniques, we have investigated the nuclear androgen receptor (ar) status an

Primary culture model of peroxisome prol
✍ Yue Xu; Sunita Iyengar; Richard L. Roberts; Scott B. Shappell; Donna M. Peehl πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 516 KB

## Abstract BRL 49653 (rosiglitazone) is a thiazolidinedione anti‐diabetic drug that activates the nuclear receptor, peroxisome proliferator‐activated receptor gamma (PPARΞ³). Pilot clinical trials have shown evidence of therapeutic activity of PPARΞ³ agonists against prostate cancer. To more effecti